Dayvigo and Pregabalin Interaction: What Patients and Prescribers Need to Know

What Is the Lemborexant-Pregabalin Interaction?

Lemborexant and pregabalin both depress central nervous system activity through distinct molecular targets, and their sedative effects add together when the drugs are taken simultaneously. The FDA-approved prescribing information for lemborexant states that co-administration with other CNS depressants "can increase the risk of CNS depression" and instructs prescribers to consider dose reduction of lemborexant or the concomitant agent.

This is a pharmacodynamic interaction, not a pharmacokinetic one. Pregabalin does not inhibit or induce CYP3A4, the enzyme that governs lemborexant's metabolism, so plasma concentrations of lemborexant are not meaningfully altered by pregabalin alone. The clinical hazard comes instead from the convergent downstream effect: amplified sedation, impaired psychomotor performance, and, in susceptible patients, respiratory compromise.

How Each Drug Produces Sedation

Lemborexant blocks orexin OX1 and OX2 receptors in the lateral hypothalamus. Orexin (hypocretin) peptides normally sustain wakefulness; blocking their receptors tips the brain toward sleep. Lemborexant is a reversible, competitive antagonist with higher affinity for OX2 than OX1, which is the pharmacological basis for its sleep-maintenance benefit demonstrated in the SUNRISE-1 and SUNRISE-2 trials [1, 2].

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn and throughout the brain. This reduces calcium influx at presynaptic terminals, decreasing release of excitatory neurotransmitters including glutamate and substance P. The result is broadly inhibitory: reduced neuronal excitability underlies pregabalin's anticonvulsant, anxiolytic, and analgesic effects as well as its sedative side-effect profile [3].

Because these two mechanisms converge on a common output (reduced CNS arousal) through entirely separate receptor systems, no single antagonist can reverse both effects simultaneously. That is clinically relevant if a patient presents with profound sedation: naloxone will not reverse lemborexant or pregabalin.

What the FDA Labels Actually Say

The lemborexant prescribing information (Eisai, revised 2023) states under Drug Interactions: "The use of lemborexant with other CNS depressants increases the risk of CNS depression. Consider dose reduction of lemborexant or the other CNS depressant because of potentially additive effects." [4] The label caps the dose at 5 mg when co-administered with moderate CYP3A4 inhibitors, but pregabalin does not fall into that category.

The pregabalin prescribing information (Pfizer, Lyrica) lists "other CNS depressants" explicitly under drug interactions and warns that "antiepileptic drugs, opioids, benzodiazepines, or other sedating medications" amplify sedation and respiratory depression risk. [5]

Pharmacokinetics: Does Pregabalin Change Lemborexant Blood Levels?

Pregabalin does not alter lemborexant plasma concentrations through a pharmacokinetic mechanism. Understanding why matters for dosing decisions.

Lemborexant's CYP3A4 Dependence

Lemborexant is primarily metabolized by CYP3A4 to several inactive metabolites. Its oral bioavailability is approximately 85%, with a half-life of 17 to 19 hours, which explains residual next-morning impairment [4]. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) increase lemborexant exposure several-fold and are contraindicated. Moderate inhibitors (fluconazole, diltiazem) require the dose to be capped at 5 mg. Inducers (rifampin, carbamazepine) substantially lower lemborexant exposure.

Pregabalin's Absence of CYP Activity

Pregabalin is not metabolized by hepatic cytochrome P450 enzymes at all. It is eliminated almost entirely unchanged through the kidneys, with renal clearance closely correlated with creatinine clearance [5]. It does not inhibit or induce CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. This means adding pregabalin to a lemborexant regimen will not raise lemborexant Cmax or AUC.

The practical implication: the interaction is purely additive sedation. There is no need to adjust lemborexant's dose on pharmacokinetic grounds when pregabalin is added, but dose reduction may still be warranted on pharmacodynamic grounds if the patient experiences excessive daytime somnolence or psychomotor impairment.

Clinical Evidence: How Much Does Combined CNS Depression Matter?

Lemborexant's Baseline Sedation Burden

In SUNRISE-2 (N=949, 12-month randomized trial), somnolence occurred in 10% of patients on lemborexant 10 mg versus 1% on placebo. Next-day residual sleepiness, measured by the Karolinska Sleepiness Scale, was dose-dependent. [2] The 5 mg dose produced less next-morning impairment than 10 mg, which is one reason the FDA label recommends starting at 5 mg.

Pregabalin's Independent Sedation Signal

A Cochrane systematic review of pregabalin for generalized anxiety disorder (9 trials, N=2,299) found somnolence in 21% to 32% of pregabalin-treated patients versus 5% to 10% on placebo, with the highest rates at doses of 300 to 600 mg per day. [6] In the fibromyalgia trial program, dizziness and somnolence were the most common adverse events leading to discontinuation at doses above 450 mg per day. [5]

No Dedicated Combination Trial Exists

No published randomized controlled trial has specifically examined the lemborexant-pregabalin combination. This is a recognized gap in the literature. The HealthRX clinical team applies a tiered risk framework for this combination based on mechanistic class overlap, individual patient comorbidity burden, and concomitant CNS depressant count (see the decision framework below).

Absent head-to-head data, pharmacovigilance databases provide indirect signal. The FDA Adverse Event Reporting System (FAERS) contains case reports of excessive sedation with orexin receptor antagonists combined with gabapentinoids, though causality assessment in spontaneous reports is inherently limited.

Severity Classification and Risk Stratification

How DDI Databases Classify This Pair

Major clinical interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) assign this combination a "moderate" to "major" interaction rating, reflecting additive CNS depression with meaningful clinical consequences if doses are not managed. The FDA label language supports a "clinically significant" classification.

Patient Factors That Escalate Risk

Several patient-specific factors convert a moderate risk into a high-risk scenario:

• Age 65 or older. Older adults clear both drugs more slowly and are more sensitive to CNS depressants. A pharmacokinetic study cited in the lemborexant label found that exposure (AUC) was 42% higher in adults over 65 compared to younger adults [4]. Pregabalin clearance also falls with declining renal function, which is prevalent in older patients.
• Obstructive sleep apnea. Both agents may worsen upper airway muscle tone during sleep. The lemborexant label includes a specific precaution for patients with compromised respiratory function [4].
• Concomitant opioid use. The three-way combination of an opioid, a gabapentinoid, and a sedative hypnotic significantly raises fatal overdose risk. The FDA issued a Drug Safety Communication in 2019 warning about gabapentinoid respiratory depression, particularly with opioids [7].
• Baseline renal impairment. Pregabalin is renally cleared; dose reduction is required when creatinine clearance falls below 60 mL per min per the Lyrica prescribing information [5].
• Alcohol use. Alcohol is a CYP3A4 substrate and CNS depressant; it amplifies sedation from both lemborexant and pregabalin. The lemborexant label contraindicates same-night alcohol use [4].

Lower-Risk Scenarios

The combination may be acceptable when pregabalin is prescribed for a chronic pain or seizure indication at a stable, low-to-moderate dose (75 to 150 mg per day), the patient is under 65, has no respiratory comorbidity, is not taking opioids, and lemborexant is kept at 5 mg. Even in this scenario, written informed consent and documentation of the risk-benefit rationale are good practice.

Dose Adjustment Recommendations

Lemborexant Dosing Strategy

The standard lemborexant starting dose is 5 mg at bedtime, with an option to increase to 10 mg if tolerated and needed. When a CNS depressant such as pregabalin is co-prescribed, maintain lemborexant at 5 mg and do not escalate to 10 mg unless a thorough reassessment confirms the patient tolerates both agents without residual impairment [4].

If the patient is already on lemborexant 10 mg and pregabalin is being added, reduce lemborexant to 5 mg before initiating pregabalin. Allow at least one week of observation at the lower dose before titrating pregabalin upward.

Pregabalin Dosing Strategy

Pregabalin titration for neuropathic pain typically starts at 75 mg twice daily and may increase to 150 mg twice daily after one week, with a maximum of 300 mg per day for most pain indications [5]. When adding pregabalin to an existing lemborexant regimen, start at 75 mg twice daily and observe for at least 7 days before escalating. For patients with creatinine clearance between 30 and 60 mL per min, the total daily dose should not exceed 150 mg per day.

When to Reconsider the Combination Entirely

If the patient requires pregabalin doses above 300 mg per day for pain control, consider replacing lemborexant with a non-pharmacological sleep intervention (cognitive behavioral therapy for insomnia, CBT-I) rather than continuing both agents. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommends CBT-I as the first-line treatment for chronic insomnia disorder, preferring it over pharmacotherapy [8].

Monitoring Parameters

Short-Term Monitoring (First 4 Weeks)

At each contact during the first four weeks of co-administration, assess:

1. Daytime somnolence using a validated tool such as the Epworth Sleepiness Scale (ESS). A score above 10 warrants dose reduction.
2. Next-morning psychomotor performance. Ask specifically about driving, operating machinery, and falls. At least one fall or near-miss is grounds for medication change.
3. Respiratory rate and oxygen saturation at clinic visits for patients with obstructive sleep apnea or COPD.
4. Subjective pain and sleep outcomes to confirm both drugs are delivering benefit that justifies the combined sedation burden.

Long-Term Monitoring

Both lemborexant (Schedule IV) and pregabalin (Schedule V) carry abuse and dependence potential. Reassess the ongoing need for both agents every 3 months. Urine drug screening is reasonable for patients at elevated misuse risk. Renal function should be checked annually because pregabalin clearance tracks creatinine clearance; dose reduction is required as renal function declines [5].

Patient Counseling Points

What to Tell Patients Before They Start

Patients starting this combination should receive clear verbal and written instructions on five points:

First, do not drive or operate heavy machinery the morning after taking lemborexant, and be especially cautious if pregabalin was also taken that night. Residual impairment from lemborexant may persist for 8 or more hours after dosing [4].

Second, alcohol is not safe to combine with either drug. Even one drink can substantially worsen next-morning sedation and coordination.

Third, call the prescriber immediately if they experience difficulty breathing during sleep, excessive daytime sedation, or confusion.

Fourth, neither drug should be stopped abruptly. Pregabalin discontinuation has been associated with withdrawal symptoms including insomnia, nausea, headache, and in rare cases, seizures [5]. Lemborexant does not carry the same seizure risk but rebound insomnia may occur.

Fifth, inform all healthcare providers, including dentists and emergency clinicians, about both medications because additional CNS depressants given during procedures compound the risk.

The Importance of the "Full Drug List" Conversation

Patients prescribed both lemborexant and pregabalin are often taking other medications for anxiety, pain, or mood. A complete medication reconciliation at every visit is not optional. A 2020 analysis of Medicare Part D claims found that 17.5% of adults aged 65 and older who filled a gabapentinoid prescription were also taking a benzodiazepine or a Z-drug, representing a high-risk polypharmacy pattern [9]. Adding a dual orexin receptor antagonist to that picture further loads the CNS depressant burden.

Special Populations

Older Adults (65 and Older)

The FDA label for lemborexant notes that clinical studies included adults up to age 88, and that older adults experienced higher drug exposure than younger adults at equivalent doses [4]. For patients 65 and older on pregabalin, 5 mg lemborexant is the ceiling dose, not the starting option. Some clinicians prefer to avoid the combination entirely in this age group and manage insomnia through CBT-I or melatonin receptor agonists with lower CNS depression potential.

Patients With Renal Impairment

Lemborexant does not require dose adjustment for renal impairment per its label [4]. Pregabalin does. For patients with creatinine clearance below 30 mL per min, pregabalin doses should be halved compared to those used in patients with normal renal function, per the Lyrica prescribing information [5]. This matters because reduced renal clearance raises pregabalin plasma concentrations, amplifying the additive sedation even further.

Pregnancy and Lactation

Lemborexant is Category not-formally-assigned under the new Pregnancy and Lactation Labeling Rule (PLLR), but animal studies showed developmental toxicity at exposures above clinical doses [4]. Pregabalin has human data suggesting increased risk of major birth defects (odds ratio approximately 1.53 in one Nordic cohort study) [10]. Neither drug is recommended during pregnancy. Insomnia during pregnancy should be managed with CBT-I as first-line therapy per the American College of Obstetricians and Gynecologists [11].

Summary Decision Framework for Co-Prescribing

The following four questions should guide every prescribing decision when lemborexant and pregabalin are both being considered:

Question 1. Is the indication for each drug clearly established and documented? If pregabalin is being used off-label for insomnia itself, it should not be combined with lemborexant.

Question 2. Has CBT-I been offered for the insomnia component? If not, offer it before initiating lemborexant, per AASM 2017 guidelines [8].

Question 3. Does the patient have any high-risk features (age 65 and older, sleep apnea, opioid use, renal impairment, alcohol use disorder)? If yes, the threshold for co-prescribing should be high, with documented rationale and shared decision-making.

Question 4. If both drugs are clinically necessary, are both at their lowest effective doses? Lemborexant should be 5 mg maximum; pregabalin should be titrated slowly with reassessment at each step.

The prescribing information for lemborexant states: "Because of the risk of next-day impairment, patients should not drive or engage in other activities requiring complete mental alertness after taking DAYVIGO." [4] That caution is amplified when any additional CNS depressant is present.